Development of supportive management to prevent docetaxel-induced peripheral neuropathy with compression therapy in patients with breast cancer.

Development of supportive management to prevent docetaxel-induced peripheral neuropathy with compression therapy in patients with breast cancer. - Development of supportive management to prevent docetaxel-induced peripheral neuropathy with compression therapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027881

Enrollment

Registered

2017-06-26

Start date

2017-06-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

sleeve and stocking

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: The patients with breast cancer who will be administered with docetaxel (75mg/BSA) (with anti-HER2).

Exclusion criteria

Exclusion criteria: 1. The patient with peripheral neuropathy with any cause. 2. The patients with previous medication with anti-cancer drug

Design outcomes

Primary

Measure	Time frame
The incidence of docetaxel-induced peripheral neuropathy with any grade 1 or higher.	—

Countries

Japan

Contacts

Public ContactKosho Yamanouchi

Nagasaki University Graduate School of Biomedical Sciences Surgery

koshoy@nagasaki-u.ac.jp095-819-7316

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026